CD171- and GD2-specific CAR-T cells potently target retinoblastoma cells in preclinical in vitro testing.
Andersch L, Radke J, Klaus A, Schwiebert S, Winkler A, Schumann E, Grunewald L, Zirngibl F, Flemmig C, Jensen MC, Rossig C, Joussen A, Henssen A, Eggert A, Schulte JH, Künkele A.
Andersch L, et al. Among authors: zirngibl f.
BMC Cancer. 2019 Sep 9;19(1):895. doi: 10.1186/s12885-019-6131-1.
BMC Cancer. 2019.
PMID: 31500597
Free PMC article.